CHILDHOOD MDS TREATED WITH AML REGIMENS

被引：0
|
作者：
HASLE, H
KERNDRUP, G
机构：
来源：
GEMATOLOGIYA I TRANSFUZIOLOGIYA | 1995年 / 40卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：18 / 18
页数：1
相关论文
共 50 条
  • [1] COMPARISON BETWEEN DIFFERENT REDUCED INTENSITY CONDITIONING REGIMENS IN AML OR MDS
    Emilio Salinas, Jose
    Flores, Yorman
    Rojas, Patricio
    Gutierrez, Catherine
    Vidal, Marcela
    Jara, Veronica
    Rivera, Elizabeth
    Campbell, James
    Jose Garcia, Maria
    Sandoval, Vicente
    Vergara, Maximiliano
    Ocqueteau, Mauricio
    Palacios, Felipe
    Sandoval, Pablo
    Sarmiento, Mauricio
    BONE MARROW TRANSPLANTATION, 2024, 59 : 287 - 287
  • [2] ISOLATED MYELOSARCOMA TREATED AS AML, WITH PROGRESSION TO MDS/MPN
    Fuentes, A.
    LaBier, G.
    Boulmay, B.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2018, 66 (02) : 440 - 440
  • [3] Secondary MDS/AML in patients treated for myeloma.
    Saso, R
    Kulkarni, S
    Powles, R
    Treleaven, J
    Wilson, K
    Swansbury, J
    Sastry, P
    Ramiah, V
    Horton, C
    Mehta, J
    Catovsky, D
    BLOOD, 1998, 92 (10) : 455A - 455A
  • [4] Role of fludarabine containing regimens in newly-diagnosed AML or MDS.
    Estey, E
    Thall, P
    Kantarjian, H
    Pierce, S
    Freireich, E
    BLOOD, 1998, 92 (10) : 232A - 233A
  • [5] Recurrent transcriptional responses in AML and MDS patients treated with decitabine
    Upadhyay, Pawan
    Beales, Jeremy
    Shah, Nakul M.
    Gruszczynska, Agata
    Miller, Christopher A.
    Petti, Allegra A.
    Ramakrishnan, Sai Mukund
    Link, Daniel C.
    Ley, Timothy J.
    Welch, John S.
    EXPERIMENTAL HEMATOLOGY, 2022, 111 : 50 - 65
  • [6] AML / MDS
    Bone Marrow Transplantation, 2002, 29 (Suppl 2) : S54 - S57
  • [7] Access to allogeneic hematopoietic SCT for patients with MDS or relapsed AML treated according to protocols of the Dutch Childhood Oncology Group
    Joris, M. M.
    Bierings, M. B.
    Egeler, R. M.
    Claas, F. H. J.
    van Rood, J. J.
    Oudshoorn, M.
    BONE MARROW TRANSPLANTATION, 2012, 47 (05) : 677 - 683
  • [8] Retrospective comparison of two myeloabalative conditioning regimens in patients with AML/MDS: a monocentric experience
    Paysant, C.
    Delage, J.
    Vincent, L.
    Laurent, N.
    Sirvent, A.
    Cartron, G.
    Vergely, L.
    Fegueux, N.
    Ceballos, P.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S439 - S440
  • [9] Access to allogeneic hematopoietic SCT for patients with MDS or relapsed AML treated according to protocols of the Dutch Childhood Oncology Group
    M M Jöris
    M B Bierings
    R M Egeler
    F H J Claas
    J J van Rood
    M Oudshoorn
    Bone Marrow Transplantation, 2012, 47 : 677 - 683
  • [10] Real-world outcomes in patients with AML and MDS treated with Azacitidine
    Prusak, E.
    Lawes, M.
    Collins, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 42 - 42
12345